- E-mailCharis.Georgiou@uib.no
- Visitor AddressJonas Lies vei 91Department of Biomedicine5009 BergenRoom5A104dB
- Postal AddressPostboks 78045020 Bergen
I finished my BSc in Chemistry from University of Leeds and then I did my MSc in Chemical biology and drug discovery at the same university. Then I moved to University of Edinburgh where I did my PhD in Structural Biology. I have stayed in Edinburgh for two more years working as a Postdoctoral fellow, before moving to the University of Bergen to work as Postdoctoral fellow in the group of Prof Ruth Brenk. My current research is focused on the identification of new inhibitors for several protein targets from Pseudomonas aeruginosa (a gram negative bacteria in the priority pathogens list of WHO). My passion and research interest is in drug discovery and fragment screening while my expertise is in the combination of computational chemistry techniques with structural biology including X-ray crystallography, binding/enzymatic assays and molecular modeling.
Jordi Juarez-Jimenez, Arun A. Gupta, Gogulan Karunanithy, Antonia S. J. S. Mey, Charis Georgiou, Harris Ioannidis, Alessio De Simone, Paul N. Barlow, Alison N. Hulme, Malcolm D. Walkinshaw, Andrew J. Baldwin and Julien Michel,Dynamic design: manipulation of millisecond timescale motions on the energy landscape of cyclophilin A. Chem. Sci.,11, 2670-2680 (2020) https://pubs.rsc.org/fa/content/articlelanding/2020/sc/c9sc04696h#!divAbstract
Alessio De Simone, Charis Georgiou, Harris Ioannidis,Arun A. Gupta, Jordi Juarez-Jimenez,Dahlia Doughty-Shenton, Elizabeth A. Blackburn, Martin A. Wear, Jonathan P. Richards, Paul N. Barlow, Neil Carragher, Malcolm D. Walkinshaw,Alison N. Hulme and Julien Michel,A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors. Chem. Sci.10, 542–547 (2019) https://pubs.rsc.org/en/content/articlelanding/2019/sc/c8sc03831g#!divAbstract
Charis Georgiou, Iain McNae, Martin Wear, Harris Ioannidis, Julien Michel and Malkolm Walkinshaw, Pushing the Limits of Detection of Weak Binding Using Fragment-Based Drug Discovery: Identification of New Cyclophilin Binders. J Mol Biol429, 2556–2570 (2017) https://www.sciencedirect.com/science/article/pii/S0022283617303170?via%3Dihub